US protection ending in 2030: Bones, joints and muscles
As of the edition of 20 October 2026, 15 drugs have US protection that ends in 2030 in bones, joints and muscles; 11 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
15 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Burosumab | Ends 2030 (computed from the first US licence) | Marketed | Kyowa Kirin | FGF23 | 1 |
| Casimersen | Ends 2030 (patent) | Marketed | Avi Biopharma | DMD | 0 |
| Dabrafenib | Ends 2030 (patent) | Marketed | Novartis | BRAF | 1 |
| Doxecitine | Ends 2030 (exclusivity) | Marketed | UCB | 0 | |
| Emapalumab | Ends 2030 (computed from the first US licence) | Marketed | Swedish Orphan Biovitrum | IFNG | 1 |
| Erenumab | Ends 2030 (computed from the first US licence) | Marketed | Amgen | CALCRL | 1 |
| Fremanezumab | Ends 2030 (computed from the first US licence) | Marketed | Teva | CALCA, CALCB | 4 |
| Galcanezumab | Ends 2030 (computed from the first US licence) | Marketed | Eli Lilly | CALCA, CALCB | 2 |
| Macimorelin | Ends 2030 (exclusivity) | Marketed | COSCIENS Biopharma | GHSR | 2 |
| Palovarotene | Ends 2030 (exclusivity) | Marketed | Ipsen | RARG | 1 |
| Raltegravir | Ends 2030 (patent) | Marketed | Merck & Co. | 0 | |
| Ravulizumab | Ends 2030 (computed from the first US licence) | Marketed | AstraZeneca | C5 | 0 |
| Sildenafil | Ends 2030 (exclusivity) | Marketed | Viatris | PDE5A | 3 |
| Tildrakizumab | Ends 2030 (computed from the first US licence) | Marketed | SUN Pharmaceutical Industries | IL23A | 1 |
| Trametinib | Ends 2030 (patent) | Marketed | Novartis | MAP2K1, MAP2K2 | 2 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2030 in bones, joints and muscles
In the product11 of these 15 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.